← Leaderboards
Tae-Wan Kim
Massachusetts General Hospital
$10,899,820
Attributed
$11,363,647
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $874.6K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,363,647 · 10
By mechanism
R01$8,728,013 · 5
R21$1,742,708 · 4
P50$892,926 · 1
Top collaborators
- John R Cirrito2 shared
- Jihye Paik1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- M Flint Beal$24,698,686
- Joshua M Kaplan$21,420,540
- Rebecca M Boumil$1,496,390
- Zhaoda Zhang$4,338,002
- Dimitri Krainc$24,610,296
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseBrainCellsMolecularAmyloid Beta-ProteinProteinsBaseFunctional DisorderAnimal ModelNeuronsPathogenesisPlayLeadEnzymesSignal TransductionPresenilinGenesAmyloid Beta-Protein PrecursorAmyloidMediatingMemoryHippocampus (Brain)Biological
Grant awards (34)
FOXO3 dependent proinflammatory transcription program of AD$475,377
R21 · FY2025 · AG · contact PI
Microglial TREM2 Interactome in Alzheimers Disease$509,123
R01 · FY2024 · AG · contact PI
Microglial TREM2 Interactome in Alzheimers Disease$509,123
R01 · FY2023 · AG · contact PI
Microglial TREM2 Interactome in Alzheimers Disease$509,123
R01 · FY2022 · AG · contact PI
Microglial TREM2 Interactome in Alzheimers Disease$509,123
R01 · FY2021 · AG · contact PI
Microglial TREM2 Interactome in Alzheimers Disease$524,623
R01 · FY2020 · AG · contact PI
Chemical Biology of Tau Missorting in Alzheimers Disease$202,500
R21 · FY2019 · NS · contact PI
Effects of ApoE-enhancing Compounds on Alzheimers Disease Phenotypes In Vivo$198,451
R21 · FY2019 · TR · contact PI
Effects of ApoE-enhancing Compounds on Alzheimers Disease Phenotypes In Vivo$253,827
R21 · FY2018 · TR · contact PI
Chemical Biology of Tau Missorting in Alzheimers Disease$243,000
R21 · FY2018 · NS · contact PI
Validating a Novel Lipid Phosphatase Target in Alzheimer's Disease$350,000
R01 · FY2015 · NS · contact PI
Validating a Novel Lipid Phosphatase Target in Alzheimer's Disease$346,501
R01 · FY2014 · NS · contact PI
Validating a Novel Lipid Phosphatase Target in Alzheimer's Disease$337,750
R01 · FY2013 · NS · contact PI
Validating a Novel Lipid Phosphatase Target in Alzheimer's Disease$350,000
R01 · FY2012 · NS · contact PI
Validating a Novel Lipid Phosphatase Target in Alzheimer's Disease$351,094
R01 · FY2011 · NS · contact PI
Screening for AD Therapeutics Based on a Novel Lipid Phosphatase Target$164,426
R21 · FY2011 · AG · contact PI
Screening for AD Therapeutics Based on a Novel Lipid Phosphatase Target$205,127
R21 · FY2010 · AG · contact PI
PROTEIN TRAFFICKING IN SPORADIC ALZHEIMER'S DISEASE$212,220
P50 · FY2009 · AG · contact PI
PROTEIN TRAFFICKING IN SPORADIC ALZHEIMER'S DISEASE$208,667
P50 · FY2008 · AG · contact PI
Natural Product Therapeutics in Alzheimer's Disease$615,907
R01 · FY2007 · AT · contact PI
PROTEIN TRAFFICKING IN SPORADIC ALZHEIMER'S DISEASE$222,039
P50 · FY2007 · AG · contact PI
Natural Product Therapeutics in Alzheimer's Disease$479,486
R01 · FY2006 · AT · contact PI
PROTEIN TRAFFICKING IN SPORADIC ALZHEIMER'S DISEASE$125,000
P50 · FY2006 · AG · contact PI
Natural Product Therapeutics in Alzheimer's Disease$477,798
R01 · FY2005 · AT
Molecular/Physiological Analyses of Presenilin Function$271,819
R01 · FY2005 · NS
PROTEIN TRAFFICKING IN SPORADIC ALZHEIMER'S DISEASE$125,000
P50 · FY2005 · AG
Natural Product Therapeutics in Alzheimer's Disease$490,053
R01 · FY2004 · AT
Molecular/Physiological Analyses of Presenilin Function$271,819
R01 · FY2004 · NS
PROTEASOMAL DYSFUNCTION IN ALZHEIMER'S DISEASE$313,001
R01 · FY2003 · AG
Molecular/Physiological Analyses of Presenilin Function$271,819
R01 · FY2003 · NS
PROTEASOMAL DYSFUNCTION IN ALZHEIMER'S DISEASE$312,508
R01 · FY2002 · AG
Molecular/Physiological Analyses of Presenilin Function$295,569
R01 · FY2002 · NS
PROTEASOMAL DYSFUNCTION IN ALZHEIMER'S DISEASE$313,266
R01 · FY2001 · AG
PROTEASOMAL DYSFUNCTION IN ALZHEIMER'S DISEASE$318,508
R01 · FY2000 · AG